In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
|Articles|May 28, 2020
Industry Welcomes Financial Support of Biotech Sector in UK
Author(s)BioPharm International Editors
The UK BioIndustry Association has stated its support of a government led funding initiative, Future Fund, which will support innovative companies in the United Kingdom that will help to ensure the country’s leading position in science, innovation, and technology.
Advertisement
The UK BioIndustry Association (BIA) has stated its support of a government led funding initiative, Future Fund, which will support innovative companies in the United Kingdom that will help to ensure the country’s leading position in science, innovation, and technology.
Run by the British Business Bank, the Future Fund, launched on Wednesday May 20, 2020, provides convertible loans to businesses that are currently impacted by COVID-19 and usually rely on equity investment. Loans worth between £125,000 (US $153,350) and £5 million (US $6.1 million) are available through government support and then third-party investors, that see potential in the pre-revenue or pre-profit businesses, can match the government commitment or provide extra investment.
“We’re very pleased to see these support measures rolled out. There are thousands of strong and promising life science companies across the UK facing severe unexpected pressures and this support will help them weather the storm. The UK is the third global hub for life sciences so this action from government is vital to ensure we do not lose that world-leading position,” said Dr. Martin Turner, head of policy and public affairs at BIA, in a May 20, 2020 press release. “The continuity grants and loans will allow hundreds of promising life science companies that are already in receipt of Innovate UK grants to emerge from the COVID-19 storm in a strong position to continue their R&D programs and grow their businesses. The disruption caused by the pandemic has made laboratory research impossible for many companies and slowed or halted clinical trials across the UK, this additional grant funding and business support will help companies make up for lost time.”
Applications for the financing initiative are now open and can be submitted via an
Sources:
Advertisement
Related to this article
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
FDA has cleared Biolojic Design’s IND for BD200, a bispecific antibody-drug conjugate targeting Trop2 and Nectin-4 whose arms can each bind either target. A global Phase 1 study in solid tumors is expected to begin in the coming weeks.
Blackstone Life Sciences will fund up to $1.5 billion of development costs through 2028 for Pfizer’s monthly GLP-1 receptor agonist berobenatide, in exchange for milestone payments tied to approval and sales. Pfizer keeps full control of the program.
Beam Therapeutics’ base-edited cell therapy risto-cel meets its primary endpoint in the BEACON sickle cell disease trial, Amgen’s CD40L antagonist dazodalibep reduces systemic disease activity in the phase 3 OASIZ-301 Sjögren’s disease trial, and ImvivaBio’s allogeneic CD19/BCMA CAR-T CTA313 sustains lupus remission through 12 months.
ProBio grants AbTis exclusive global rights to a discovery-stage oncology antibody for development as a site-specific antibody-drug conjugate.
ImvivaBio’s off-the-shelf CD19/BCMA CAR-T cell therapy CTA313 kept 88% of evaluable patients with refractory lupus in DORIS remission at Month 12, according to longer-term phase 1 data presented at ACR Convergence 2026.
Beam’s base-edited cell therapy met its primary endpoint in the BEACON trial, and a U.S. biologics license application is planned as early as year-end.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
4
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
5